MTL-CEBPA

Cat. No.:	HY-132607
CAS No.:	2862057-05-2
Molecular Weight:	13464.27
Target:	MicroRNA
Pathway:	Epigenetics
Storage:	-20°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

MTL-CEBPA

BIOLOGICAL ACTIVITY

Description	MTL-CEPBA is a small activating RNA targeting for upregulation of C/EBPα. MTL-CEPBA has anti-inflammatory and anti-cancer activity[1].
In Vitro	MTL-CEBPA does not significantly change total human $CD45^+$ cells, and T lymphocytes ($hCD4^+$ and $hCD8^+$ T cell subsets) in PB. However, MTL-CEBPA treatment increases $CD16^+$ granulocytes and $CD14^+$ monocytes in peripheral blood (PB)[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	MTL-CEBPA (iv; 3 mg/kg; on days 1, 3, and 5) demonstrates the specific activation of its target C/EBPα mRNA and its downstream gene p21 in naive hu-NSG mice[1]. MTL-CEBPA restores LPS-induced (12.5 μg; ip; single dose) reduction of C/EBPα and downregulates several genes associated with immune and inflammatory response in an LPS-stimulated humanized NSG model[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Reebye V, Huang KW, Lin V, et al. Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer. Oncogene. 2018;37(24):3216-3228.

[2]. Combination therapies comprising C/EBPα-targeted short-activating RNA (saRNA). WO2022229644A1

[3]. Jiehua Zhou, et al. Anti-inflammatory Activity of MTL-CEBPA, a Small Activating RNA Drug, in LPS-Stimulated Monocytes and Humanized Mice. Mol Ther. 2019 May 8;27(5):999-1016.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA